For the bone mineral density secondary outcomes , total hip bone mineral density increased more in the teriparatide to denosumab group ( 66 % [ 95 % CI 53-79 ] ) than in the denosumab to teriparatide group ( 28 % [ 13-42 ] , p = 00002 ) , but had the greatest increase in the combination to denosumab group ( 86 % [ 71-100 ] ; p = 00446 vs the teriparatide to denosumab group , p < 00001 vs the denosumab to teriparatide group ) .